'Europe’s rare cancer
community calls for
a more radical approach'



Anna Wagstaff




The genomic era offers enormous potential for patients with rare cancers, but progress is being
held back by structures that separate research from care, regulatory practices that penalise
small patient populations, and rules that restrict close working between researchers,
companies, patients and regulators.

Department of Health publishes guidance on exceptional cases processes


Wednesday, January 21, 2009


The Department of Health has published Defining Guiding Principles for Processes supporting Local Decision Making about Medicines.

Rarer Cancer Forum have produced a booklet to advice consultants on appealing negative funding decisions from PCT's...download booklet here

Rarer Cancers Forum carried out an audit of the policies and processes used by PCTs to determine exceptional funding requests. The findings of the audit were made public in an RCF report entitled Taking Exception (August 2008).

Rarer Cancers Forum carried out an audit of the policies and processes used by PCTs to determine exceptional funding requests. The findings of the audit were made public in an RCF report entitled Taking Exception (August 2008).

Department of Health publishes guidance on exceptional cases processes


Wednesday, January 21, 2009


The Department of Health has published Defining Guiding Principles for Processes supporting Local Decision Making about Medicines.

see article here

Excellent webcast featuring Brian Druker MD and Neil Shah MD talking about CML in general with a brief overview for newly diagnosed patients and then new drug therapy options for patients with resistant disease. Hosted by the Leukaemia and Lymphoma Society U.S.A

more information on DH web site .....here

Winter 2008/2009 Update on Targeted Radiowave Therapy Research

I am pleased to report we continue to make excellent progress in our use of the Kanzius radiofrequency field device to treat human cancers. Since the last update, a manuscript has just been accepted in which we prove we can target gold nanoparticles to malignant cells that express a specific type of receptor at the surface of the cell. This leads to increased levels of the gold nanoparticles in the cancer cells. This enhanced uptake of the nanoparticles led to complete killing of the cancer cells following treatment in the Kanzius radiofrequency field. This paper will be published in late December or early January in the Journal of Experimental Therapeutics. This will be the first manuscript that proves that we can target nanoparticles to a specific abnormality on cancer cells and increase the killing by getting more nanoparticles into the cells.